Navigation Links
Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
Date:10/4/2010

er (median 14.5 months versus 12.5 months; hazard ratio 0.85; 95 percent CI: 0.70-1.04), the improvement in overall survival (co-primary endpoint) in the Vectibix arm did not achieve statistical significance (p=0.12) in the same patient population.
  • The addition of Vectibix to chemotherapy in the '181' trial resulted in greater than a three-fold improvement (35 percent versus 10 percent) in response rate in the wild-type KRAS patient population, as measured by a blinded central review.
  • Tumor KRAS status was ascertained in 91 percent of the 1,186 patients enrolled in the '181' trial, the highest number ever prospectively reported for a second-line trial.
  • In this study, the addition of Vectibix had no positive or negative effect on PFS or OS in patients with tumors harboring activating KRAS mutations.

  • "The response rate seen in the '181' trial is among the highest ever reported in the second-line metastatic colorectal cancer setting," said Emily Chan, M.D., Ph.D., Assistant Professor of Medicine, Vanderbilt-Ingram Cancer Center and '181' study investigator and author. "Additionally, the tissue acquisition from both the '181' and '203' studies has yielded a large repository of informative data regarding the KRAS biomarker, and holds the potential of providing even more information in the future."

    In general, adverse events rates were comparable across arms in both studies, with the exception of known toxicities associated with anti-EGFR therapy, such as rash, diarrhea, and hypomagnesemia. Vectibix-related grade 3/4 infusion reactions were reported in less than one percent of patients.

    Originally designed to compare the treatment effect in the overall mCRC patient population, both studies were amended to analyze outcomes with respect to the presence or absence of activating mutations in KRAS in the tumor itself. These are the first Phase 3 studies to prospectively analyze the effect of
    '/>"/>

    SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
    2. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
    3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
    4. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
    5. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
    6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
    7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
    8. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
    9. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
    10. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
    11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/29/2015)... June 29, 2015 BioNano Genomics, Inc., the ... research institutes, announced today that a collaboration led by ... in the creation of the first comprehensive analysis of ... molecule methods for sequencing and genome mapping. This study, ... comprehensive analysis of the contiguous diploid human genome assembly ...
    (Date:6/29/2015)... , June 29, 2015 According ... (DNA, RNA, XNA), by Application (Diagnostics, Therapeutics, R&D), by Technology ... & Pharmaceutical Companies, CRO) - Global Forecast to 2020", published ... $244.93 Million by 2020 from $107.56 Million in 2015, at ... T ables and 67 F igures ...
    (Date:6/29/2015)... , June 29, 2015 ... medical information products and services, today announced the highlights ... to the 2014 Journal Citation Reports® (JCR) published by ... Factors increase from 2013 to 2014, ahead of the ... the top rank in 62 subject categories, up from ...
    (Date:6/26/2015)... (PRWEB) , ... June 26, 2015 , ... ... Department of Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) awarded a ... as vomitoxin in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. This 5 ...
    Breaking Biology Technology:BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2
    ... Small Companies In America, UNION CITY, Calif., Oct. ... products company manufacturing point-of-care,blood chemistry analysis systems, announced today ... named "Entrepreneur of,the Year" by Forbes Magazine in its ... ranked eleventh of the "200 Best Small Companies in,America." ...
    ... Held by GlaxoSmithKline Since June 2006, PHILADELPHIA ... The Thomson Corporation (NYSE: TOC ; TSX: ... worldwide research and,business communities, today announced the availability ... on drugs and therapies. "Who is,Making the Biggest ...
    ... AURORA, ON, Oct. 15 /PRNewswire-FirstCall/ - Helix BioPharma Corp.,(TSX: ... F. McElroy,has resigned as Chairman and a director of ... had a long involvement with the Company since its,amalgamation ... "On behalf of the Company, I thank him for ...
    Cached Biology Technology:Abaxis CEO Clint Severson Named 'Entrepreneur of the Year' by Forbes Magazine 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 3Helix BioPharma Chairman resigns 2
    (Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
    (Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
    (Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
    Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
    ... 2011 (Rome, Italy) -- Researchers speaking in the second ... Pathogenesis, Treatment and Prevention (IAS 2011) have today provided ... and alerted delegates to the challenges that developing countries ... antiretroviral therapy (ART) coverage. The presentations reflect the ...
    ... Small-scale fisheries could pose a more serious threat to ... University of Exeter, published today (19 July) in the ... shows that tens of thousands of turtles from across ... small-scale fisheries. Focusing on fisheries in Peru, the ...
    ... use various appendages to move across surfaces prior to ... jerky form of movement known as "twitching" motility, which ... called type IV pili, or TFP. ... a professor of bioengineering and of chemistry and biochemistry ...
    Cached Biology News:Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS 2Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS 3Study shows small-scale fisheries' impact on marine life 2UCLA study shows bacteria use Batman-like grappling hooks to 'slingshot' on surfaces 2
    ... The Neural Stem Cell Expansion Kit - Neurosphere ... neural stem cell expansion as neurospheres in ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
    DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
    ... E. coli strain containing an overproducing clone ... Reverse Transcriptase catalyzes the polymerization of DNA ... Full-length copies of large mRNAs, >10 kb, ... a much lower RNase H activity than ...
    ... RQ1 RNase-Free DNase is a preparation ... or double-stranded DNA to produce 3-hydroxyl ... use in applications where maintaining the ... DNase is qualified for use with ...
    Biology Products: